Fortress or Island? Assessing the Impact of the European Health Data Space and Cloud Sovereignty Requirements on European Digital Health and Life Sciences
- Nelson Advisors
- 4 hours ago
- 10 min read
The European Union has embarked on an ambitious regulatory effort to establish digital and data sovereignty across critical economic sectors. At the centre of this strategy lies the European Health Data Space (EHDS) Regulation (EU) 2025/327 which officially entered into force on March 26th, 2025.
By creating a single market for electronic health data, the European Commission seeks to empower citizens, streamline cross-border clinical care and unleash secondary health data reuse for research, public policy, and healthcare innovation. However, the EHDS does not operate in a regulatory vacuum. It intersects directly with the EU’s evolving cloud sovereignty frameworks, including the candidate European Cybersecurity Certification Scheme for Cloud Services (EUCS) under the European Union Agency for Cybersecurity (ENISA) and the Cloud and AI Development Act (CADA).
This regulatory convergence presents a complex economic and strategic trade off. Proponents argue that combining strict health data governance with sovereign cloud mandates will construct a protective regulatory moat.
This moat is intended to shield European healthtech firms, cloud vendors, and research institutions from foreign competition, creating a self-sustaining domestic market. Conversely, industry leaders and global investors warn that these frameworks threaten to transform Europe into an isolated island.
Oversimplified data localisation mandates, ambiguous protections for intellectual property and trade secrets and operational barriers for global hyper scalers risk alienating international capital, reducing pharmaceutical research and development (R&D) investments, and starving European healthcare ecosystems of cutting-edge technology.
Architecture of the EHDS: Timelines, Governance and Data Localisation Protocols
The EHDS framework divides health data processing into two distinct operational domains: primary use and secondary use. Primary use governs the cross-border processing of electronic health records (EHR) to facilitate direct patient care, utilizing the MyHealth@EU infrastructure.
Secondary use establishes a regulated mechanism under the HealthData@EU network, allowing public institutions, academic researchers, and commercial entities to re-use anonymised or pseudonymised health data for scientific, regulatory, and innovative activities. The implementation follows a phased rollout spanning a decade to allow Member States and market participants to adapt their technical and legal architectures.
Implementation Date | Operational Scope | Targeted Data Categories & Milestones |
26 March 2025 | Entry into Force | Legal adoption finalized; commencement of the transition and national setup phase. |
26 March 2029 | Phase 1 Application | Mandatory cross-border exchange for primary use (Patient Summaries and ePrescriptions/eDispensations). Secondary use rules become active for most Electronic Health Record (EHR) data categories. |
26 March 2031 | Phase 2 Application | Primary use exchange expands to complex diagnostics (medical images, lab results, hospital discharge reports). Secondary use applies to high-sensitivity categories, including genomic data. |
March 2035 | International Expansion | Third countries and international organizations can formally apply to join the HealthData@EU infrastructure for secondary use. |
Access for secondary use is strictly mediated by newly created national Health Data Access Bodies (HDABs). Data holders including public hospitals, private healthcare providers and pharmaceutical manufacturers are legally mandated to make eligible electronic health data available to HDABs upon request. Once an HDAB issues a data permit following a rigorous purpose evaluation, access is granted exclusively within a Secure Processing Environment (SPE). Data users are barred from downloading individual-level personal data from SPEs; only fully anonymised, aggregated analytical results may be extracted.
Furthermore, data processing is restricted to a pre-approved list of secondary purposes, such as scientific research, public health surveillance, and algorithm validation. The regulation explicitly prohibits secondary processing for targeted commercial advertising, underwriting decisions, or setting insurance premiums.
The final EHDS text introduces targeted data localisation requirements. Personal health data processed by HDABs and SPEs for anonymisation or pseudonymisation must be stored and processed within the European Union, unless transferred to a third country benefiting from a European Commission adequacy decision under Article 45 of the General Data Protection Regulation (GDPR). Non-personal, anonymized health data generated within SPEs is classified as highly sensitive due to potential re-identification risks. Consequently, the transfer of non-personal health data to third countries is constrained where foreign courts or authorities attempt to compel access without established mutual legal assistance treaties or reciprocal jurisdictional safeguards.
Sovereign Cloud Frameworks: EUCS and CADA's Four Tier Assurance Paradigm
The technical feasibility of the EHDS relies heavily on the underlying cloud and server infrastructure hosting SPEs and national HDAB connections. The regulatory requirements governing these cloud systems have been codified under the Cloud and AI Development Act (CADA) and the ENISA-led candidate European Cybersecurity Certification Scheme for Cloud Services (EUCS). CADA establishes a standardised four-tier Cloud Sovereignty Assurance Level framework that bridges broad digital policy with concrete technical procurement criteria across the Union.
CADA Assurance Level | Target Sensitivity & Expected Public Market Share | Core Technical, Personnel, and Jurisdictional Requirements | Hyperscaler & Market Eligibility |
Level 1 (Baseline) | Standard public systems; ~70% of public procurement contracts. | Data storage and infrastructure located in the EU. Non-EU support allowed with full traceability. Self-assessed compliance. | Fully accessible to global hyperscalers (AWS, Azure, Google Cloud). |
Level 2 (Data Sovereignty) | Regulated business data; ~20% of public procurement contracts. | Providers, subcontractors, and assets located in the EU. EU-based technical support. Independent audit showing immunity from non-EU data access orders. "Substantial" cybersecurity certification. | Achievable for hyperscalers via local sovereign joint ventures (e.g., Google with Proximus or Thales/S3NS). |
Level 3 (Digital Resilience) | Mission-critical infrastructure; <10% of public procurement contracts. | Data exclusively in the EU. All personnel must be EU citizens holding security clearances. Headquartered, owned, and controlled within the EU (unless granted a Commission exception). | Global hyperscalers generally excluded; reserved for domestic European providers or sovereign JVs. |
Level 4 (Full Sovereignty) | Highly classified national security workloads; ~1% of public procurement contracts. | Complete operational and legal independence from non-EU jurisdictions. Complete supply chain control and source-code transparency. "High" cybersecurity certification. | Foreign-controlled entities completely excluded. No cloud provider currently satisfies this standard full-stack. |
The regulatory friction within CADA and EUCS originates from foreign extraterritorial access laws, specifically the US Clarifying Lawful Overseas Use of Data (CLOUD) Act and Section 702 of the Foreign Intelligence Surveillance Act (FISA). Under the US CLOUD Act, US-headquartered cloud vendors can be compelled by US law enforcement to produce data under their legal control, regardless of whether that data resides on servers physically located within the territorial borders of an EU Member State.
To mitigate foreign legal reach, higher CADA tiers require providers to be legally independent of foreign parent companies. While Level 1 and Level 2 allow global hyperscalers which currently command approximately 70% of the European cloud market to participate through regional sovereign controls or local partnerships (such as Google’s ventures with Thales in France or Proximus in Belgium), Levels 3 and 4 impose ownership and workforce requirements that exclude non-EU parent entities.
As a result, European cloud providers like OVHcloud, Scaleway, and Deutsche Telekom natively align with Level 3 architectures, but they remain constrained by smaller infrastructure footprints and limited capital compared to global rivals.
The Life Sciences Dilemma: Trade Secret Vulnerabilities and R&D Investment Flight
While sovereign cloud policies target digital infrastructure, the secondary data sharing provisions under the EHDS introduce direct commercial friction for the life sciences and biopharmaceutical sectors. The central point of contention is EHDS Article 52, which mandates that electronic health data containing intellectual property (IP), trade secrets, or regulatory data protection must be made available for secondary use upon request.
Industry associations, including the European Federation of Pharmaceutical Industries and Associations (EFPIA), Digital Europe, MedTech Europe, EUCOPE, and COCIR—have highlighted major structural vulnerabilities in this setup. Unlike traditional voluntary frameworks where data holders negotiate access bilaterally, the EHDS forces data holders to submit to the binding authority of national HDABs.
Biopharmaceutical developers argue that pre-commercial clinical trial datasets, curated proprietary registries, proprietary data enrichment techniques, and AI training corpora represent core trade secrets whose public cataloging or third-party access could compromise commercial value. Although Article 52 permits an HDAB to deny a data permit if sharing poses an unmitigable risk of IP or trade secret infringement, HDABs currently lack harmonised guidelines or specialised task forces to accurately quantify the commercial risk of complex biomedical datasets.
This legal ambiguity comes at a time when Europe's life sciences competitiveness is facing structural headwinds relative to the United States and China.
Key Competitiveness Metric v | European Union | United States | China |
Annual R&D Spending Growth Rate (2010–2022) | 4.4% (€27.8bn to €46.2bn) | 5.5% | 20.7% |
Share of Global Clinical Trial Starts (2013–2023) | Declined by 50% | Sustained dominance in Phase I–III trials | Accelerated expansion across all phases |
New Molecular Entities (NMEs) Introduced (2023) | Fell behind China | Leading global origin site | Surpassed the EU in total NME discoveries |
New Active Substance (NAS) Approvals (Past Decade) | Decreased by 20% | Steady growth | Increased by 470% |
Use of Expedited Regulatory Review Pathways (2024) | 0% of approved NAS | 53% of approved NAS | Accelerated adoption |
Average Regulatory Approval Timelines (2024) | 430 days | 356 days | 390 days |
Gross Value Added (GVA) per Hour Worked (Pharma) | Baseline benchmark | Double the EU productivity level | Rapidly expanding productivity |
The diverging R&D trajectories shown in the data underscore a broader structural shift. The combination of lengthy regulatory review cycles, limited use of expedited review mechanisms, and compulsory secondary data sharing under EHDS Article 52 risks driving biopharmaceutical clinical trials and research capital out of Europe. If global life sciences sponsors perceive that proprietary trial data submitted inside the EU could be requested by commercial competitors via HDAB permits, capital allocation will increasingly shift toward jurisdictions offering stronger data exclusivity guarantees, such as the United States.
Market Dynamics: Domestic Vendor Moats Versus Global Capital Isolation
The economic consequences of Europe's health sovereignty push unfold along two distinct vectors: the potential creation of a protected domestic market for European technology vendors, and the competing risk of global capital isolation across the broader healthtech and life sciences sectors.
The protective fortress model operates primarily through structural advantages created for domestic cloud providers and software vendors. By reserving Level 3 and Level 4 cloud workloads exclusively for EU-owned and EU-headquartered entities, CADA constructs a legally protected public procurement market. This environment guarantees demand for regional infrastructure providers such as OVHcloud, Scaleway, Hetzner, and Deutsche Telekom, safeguarding their investments in sovereign public health platforms.
Simultaneously, the EHDS harmonises electronic health record standards, diagnostic classifications, and e-prescription formats across all 27 Member States. This technical unification removes historical national fragmentation, enabling European digital health firms to scale solutions across the entire Union under a single regulatory framework. Furthermore, the stringent operational criteria have incentivized novel hybrid corporate structures, encouraging foreign tech giants to enter sovereign joint ventures with European telecommunications firms, thereby embedding advanced capabilities within EU-controlled legal entities.
Conversely, the isolated island model highlights deep structural risks to scale, private capital formation, and scientific leadership. European cloud providers currently hold a collective 15% share of the domestic market, with leading regional players holding roughly 2% each.
Walled-off public procurement cannot immediately overcome this compute capacity deficit. Restricting high-sensitivity health data processing to local infrastructure creates operational bottlenecks for training large-scale multimodal artificial intelligence models, as European cloud vendors struggle to match the specialised hardware and high-performance compute clusters operated by global hyper scalers.
This infrastructure bottleneck is compounded by capital allocation risks within private markets. Early-stage healthtech ventures and biopharmaceutical startups rely heavily on venture capital, which demands clear global scalability and robust intellectual property protection. Compulsory secondary data sharing under EHDS Article 52, paired with legal ambiguity surrounding trade secrets, creates significant valuation uncertainty. If foreign institutional investors conclude that proprietary health software models or curated biomedical datasets risk exposure to commercial rivals through administrative access permits, international capital will increasingly bypass European startups in favor of US or Asian entities. Finally, structural barriers governing cross-border transfers risk decoupling European scientists from global scientific networks. Because third-country institutions are barred from directly accessing the HealthData@EU network until at least 2035, European researchers face institutional isolation, limiting their participation in large-scale international clinical studies and multi-jurisdictional epidemiological research.
Synthesis: Policy Path and Strategic Realities
The combined implementation of the European Health Data Space and sovereign cloud frameworks establishes a pronounced economic duality. In the cloud and software infrastructure domain, CADA’s higher assurance tiers successfully construct a regulatory fortress, shielding domestic cloud vendors from direct foreign competition within public sector health procurement. However, in the capital-intensive life sciences and biotechnology sectors, the EHDS framework risks creating an island, driving clinical trials, R&D capital, and venture investment away from the Union due to unresolved trade secret exposure and administrative processing hurdles.
To prevent structural isolation while preserving the public health benefits of the EHDS, European policymakers and industry stakeholders can adopt several targeted adjustments:
The European Commission must prioritise binding implementing acts under Article 52 to establish clear, objective criteria for protecting trade secrets, early-stage R&D data, and proprietary AI corpora. Establishing dedicated IP task forces within national Health Data Access Bodies will ensure that access permits are evaluated with rigorous commercial and legal oversight.
Regulators should maintain practical flexibility within CADA Level 2 and Level 3 frameworks to accommodate sovereign hybrid joint ventures. Allowing European entities to manage legal governance and operational encryption while leveraging global high-performance compute hardware ensures that health researchers retain access to state-of-the-art AI infrastructure.
To reverse the decade-long decline in European clinical trials, Member States must modernize regulatory review pathways and expand the use of expedited approval channels. Aligning EHDS secondary access mechanisms with existing Clinical Trials Regulation frameworks will restore commercial predictability for global life sciences sponsors.
Ultimately, the long-term success of European health data sovereignty depends on maintaining a delicate balance. If regulatory execution successfully combines robust data privacy with strong protections for trade secrets and open access to high-performance computing, the EHDS can function as a dynamic single market for digital health.
However, if policy enforcement creates rigid operational barriers without protecting commercial innovation, Europe risks becoming a sheltered fortress for local vendors but an isolated island cut off from global capital and scientific progress.
Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Follow Nelson Advisors LinkedIn Page > https://www.linkedin.com/company/nelson-advisors/
Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
#VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada
Comments